TAYTULLA
Peaknorethindrone acetate and ethinyl estradiol, and ferrous fumarate
NDAORALCAPSULE
Approved
Apr 2013
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
3/8 — Basic
TAYTULLA (norethindrone acetate and ethinyl estradiol, and ferrous fumarate) by Ichnos Glenmark Innovation is ovulation. First approved in 2013.
Drug data last refreshed 12h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TAYTULLA is an oral combined oral contraceptive containing norethindrone acetate, ethinyl estradiol, and ferrous fumarate in capsule form. It prevents ovulation to provide contraceptive efficacy. The product is indicated for pregnancy prevention in women of reproductive age.
$0.030BPart D
PeakMature contraceptive product in peak commercial phase with modest Part D utilization suggesting stable but not explosive market demand.
Mechanism of Action
ovulation.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
TAYTULLA currently shows zero linked job openings, reflecting its mature lifecycle stage and modest commercial footprint. Career opportunities exist primarily in brand management, sales, and market access roles focused on defending market share in a competitive category.
Brand ManagerField Sales Representative
Worked on TAYTULLA at Ichnos Glenmark Innovation? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.